Phase I Trial of Temozolomide Plus O⁶-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma

A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding

1976 • 225,752 citations

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

1976 • 200,127 citations

MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma

2005 • 6,591 citations

Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating Agents

2000 • 2,127 citations

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas

1995 • 1,359 citations

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

2000 • 940 citations

MGMT: its role in cancer aetiology and cancer therapeutics

2004 • 788 citations

Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide

2002 • 777 citations

Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse

1999 • 762 citations

Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents.

1990 • 736 citations

Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint radiation therapy oncology group and eastern cooperative oncology group study

1983 • 600 citations

Structure, Function, and Inhibition of O6-Alkylguanine-DNA Alkyltransferase

1995 • 502 citations

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

1992 • 483 citations

Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents.

1990 • 460 citations

DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

1998 • 413 citations

Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.

1983 • 394 citations

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

1987 • 386 citations

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

2001 • 373 citations

Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.

1998 • 300 citations

Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine.

1996 • 245 citations

Repair of DNA containing O ⁶ ‐alkylguanine

1992 • 241 citations

Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents.

1991 • 229 citations

The role of O6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis

1985 • 224 citations

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma

1997 • 221 citations

Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.

1998 • 214 citations

O6-benzylguanine and its role in chemotherapy.

1997 • 214 citations

DNA alkylation by the haloethylnitrosoureas: Nature of modifications produced and their enzymatic repair or removal

1990 • 213 citations

Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells

1993 • 195 citations

Phase II Trial of Carmustine Plus O⁶-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant Glioma

2002 • 191 citations

Regulation of Repair of Alkylation Damage in Mammalian Genomes

1993 • 164 citations

Mechanism of inactivation of human O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine

1993 • 152 citations

DNA crosslinking and cytotoxicity in normal and transformed human cells treated with antitumor nitrosoureas.

1980 • 151 citations

Activity of temozolomide in the treatment of central nervous system tumor xenografts.

1995 • 145 citations

Therapy of adult malignant brain tumors: what have the clinical trials taught us?

1986 • 145 citations

Pulmonary Toxicity Associated with Bischloroethylnitrosourea (BCNU)

1979 • 140 citations

O⁶-Alkylguanine-DNA alkyltransferase activity in human brain and brain tumors

1984 • 137 citations

The basis for current treatment recommendations for malignant gliomas

1994 • 135 citations

O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.

1999 • 127 citations

O6-Alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts

1989 • 122 citations

3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity

1996 • 121 citations

O6 alkylguanine-DNA alkyltransferase activity in human myeloid cells.

1985 • 113 citations

Phase I Trial of Carmustine Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma

2000 • 112 citations

DNA Mismatch Binding and Incision at Modified Guanine Bases by Extracts of Mammalian Cells: Implications for Tolerance to DNA Methylation Damage

1994 • 108 citations

Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.

2000 • 106 citations

Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.

1992 • 105 citations

Enhancement of Nitrosourea Activity in Medulloblastoma and Glioblastoma Multiforme

1992 • 102 citations

Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.

1996 • 100 citations

Chemotherapy of Primary Brain Tumors

1985 • 99 citations

Clinically significant pharmacokinetic drug interactions between antiepileptic drugs

1999 • 98 citations

Potentiation of temozolomide and BCNU cytotoxicity by O6-benzylguanine: a comparative study in vitro

1996 • 98 citations

Modulation of Mammalian O⁶-Alkylguanine-DNA Alkyltransferase in vivo by O⁶-Benzylguanine and its Effect on the Sensitivity of a Human Glioma Tumor to l-(2-chloroethyl)-3-(4-methylcyclohexyl)-l-nitrosourea

1990 • 95 citations

Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: A phase II study

2001 • 93 citations

Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide

1994 • 87 citations

Inactivation of O6-methylguanine-DNA methyltransferase and sensitization of human tumor cells to killing by chloroethylnitrosourea by O6-methylguanine as a free base.

1986 • 86 citations

Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6- benzylguanine plus BCNU

1996 • 85 citations

O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU

1996 • 83 citations

O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings.

1998 • 82 citations

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

2002 • 81 citations

TRANSCRIPTIONAL ACTIVATION OF CYTOCHROME P450 GENES BY DIFFERENT CLASSES OF CHEMICAL INDUCERS

1998 • 80 citations

Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts

1984 • 75 citations

Treatment of subcutaneous and intracranial brain tumor xenografts withO 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea

1993 • 70 citations

Reduction of O6-alkylguanine-DNA alkyltransferase activity in HeLa cells treated with O6-alkylguanines.

1985 • 69 citations

O6-Alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications

1994 • 68 citations

O6-methylguanine residues elicit DNA repair synthesis by human cell extracts

1993 • 68 citations

DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d] -1,2,3,5-tetrazin-4(3H)-one.

1984 • 67 citations

Effect of O6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents.

1986 • 67 citations

Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study

2004 • 66 citations

Potentiation of nitrosourea cytotoxicity in human leukemic cells by inactivation of O6-alkylguanine-DNA alkyltransferase.

1988 • 63 citations

Effect of single and multiple administration of an O ? 6 -benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model

1997 • 59 citations

Comparison of the inactivation of mammalian and bacterial O⁶-alkylguanine-DNA alkyltransferases by O⁶-benzylguanine and O⁶-methylguanine

1991 • 55 citations

Metabolism of O6-benzylguanine, an inactivator of O6-alkylguanine-DNA alkyltransferase.

1994 • 54 citations

Exposure of HeLa cells to 06-alkylguanines increases sensitivity to the cytotoxic effects of alkylating agents

1985 • 54 citations

Phase II study of neoadjuvant 1, 3‐bis (2‐chloroethyl)‐1‐nitrosourea and temozolomide for newly diagnosed anaplastic glioma

2004 • 47 citations

Human liver oxidative metabolism of O6-benzylguanine

1995 • 47 citations

Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.

1999 • 46 citations

Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and cis-diamminedichloroplatinum(II) in human glial-derived cell lines.

1987 • 43 citations

O 6-Benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas

2004 • 43 citations

Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine

1989 • 39 citations

Delayed repletion of O6-methylguanine—DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity

2003 • 39 citations

Inhibition of O⁶-alkylguanine-DNA-alkyltransferase activity potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea

1987 • 31 citations

Determination of 8-oxoguanine in human plasma and urine by high-performance liquid chromatography with electrochemical detection

1999 • 22 citations

Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate.

1995 • 22 citations

Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status

2000 • 19 citations

Preclinical approach for identifying drug interactions

1998 • 14 citations